Houston Methodist's Roberta Schwartz and Texas A&M University's Dr. Roderic Pettigrew shared their thought leadership at a recent panel for Houston Tech Rodeo. Photos courtesy

The medical field is full of problems to solve — how to improve patient care, new diseases to treat, extending but also improving quality of life, and so much more. It's an industry that needs innovation — and in many cases, that means introducing new technologies and ideas.

At last week's Houston Tech Rodeo health tech saloon, two experts weighed in on the discussion. Roberta Schwartz, chief innovation officer of Houston Methodist, and Dr. Roderic Pettigrew, dean of the Intercollegiate School of Engineering Medicine at Texas A&M University, discussed how they view the health care industry's future — and what they are doing to make sure future health care providers and innovators are ready.

“You want the next generation to get equally as excited about what’s happening in that world (of health tech) and realize how much opportunity there is to disrupt the field of health care,” Schwartz says on the panel. “It’s so natural to us at Houston Methodist to say, ‘please come along and see the opportunities there are and seize them.’”

The panelists noted on where the conversation was taking place — TAMU's new EnMed building, which was constructed and dedicated to engineering medical students. Dr. Pettigrew says the new field is meant to train problem solvers.

“When you consider scientific progress throughout history and in the future, you realize that technological innovation is the engine of scientific progress,” he says. “When you think about what profession in our society solves problems for the benefit of society, it’s engineering."

The full panel recording is available on this week's Houston Innovators Podcast. Listen to it below — or wherever you stream your podcasts — and subscribe for weekly episodes.



Photo courtesy of Houston Methodist

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.